Repros Therapeutics Company Profile (NASDAQ:RPRX)

About Repros Therapeutics

Repros Therapeutics logoRepros Therapeutics, Inc. is a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. The Company's product candidates include enclomiphene, which is a single isomer of clomiphene citrate, an orally active small molecule compound, and Proellex, which is an orally administered selective blocker of the progesterone receptor in women, for the treatment of uterine fibroids and endometriosis. Enclomiphene is for the treatment of secondary hypogonadism in overweight men wishing to restore normal testicular function. The Company's Proellex product candidate for female reproductive health is a chemical entity, which acts as a selective blocker of the progesterone receptor. It is being developed for the treatment of symptoms associated with uterine fibroids and endometriosis The Company has an active Investigational New Drug (IND) for the vaginal delivery of Proellex for the treatment of uterine fibroids.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Pharmaceuticals
  • Exchange: NASDAQ
  • Symbol: RPRX
  • CUSIP: 76028H20
Key Metrics:
  • Previous Close: $2.01
  • 50 Day Moving Average: $1.952
  • 200 Day Moving Average: $1.666
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: Infinity
  • P/E Growth: -0.100
  • Market Cap: $48.76M
  • Outstanding Shares: 24,319,000
  • Beta: -0.19
Additional Links:
Companies Related to Repros Therapeutics:

Analyst Ratings

Consensus Ratings for Repros Therapeutics (NASDAQ:RPRX) (?)
Ratings Breakdown: 1 Sell Rating, 3 Hold Ratings
Consensus Rating:Hold (Score: 1.75)
Consensus Price Target: $2.00 (0.25% downside)

Analysts' Ratings History for Repros Therapeutics (NASDAQ:RPRX)
Show:
DateFirmActionRatingPrice TargetDetails
2/9/2016Piper Jaffray Cos.Reiterated RatingNeutralView Rating Details
12/4/2015Brean CapitalReiterated RatingHoldView Rating Details
10/30/2015Ladenburg ThalmannDowngradeBuy -> NeutralView Rating Details
10/30/2015Bank of America Corp.DowngradeNeutral -> UnderperformView Rating Details
7/28/2015LaidlawReiterated RatingBuy$28.00View Rating Details
8/29/2014Ascendiant Capital MarketsReiterated RatingPositiveView Rating Details
(Data available from 8/28/2014 forward)

Earnings

Earnings History for Repros Therapeutics (NASDAQ:RPRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2016        
8/9/2016Q216($0.20)($0.18)ViewN/AView Earnings Details
5/10/2016Q1($0.22)($0.20)ViewN/AView Earnings Details
3/14/2016Q4($0.27)($0.26)ViewN/AView Earnings Details
11/9/2015Q3($0.29)($0.27)ViewN/AView Earnings Details
8/10/2015Q2($0.26)($0.32)ViewN/AView Earnings Details
3/16/2015Q414($0.34)($0.31)ViewN/AView Earnings Details
11/10/2014Q314($0.39)($0.32)ViewN/AView Earnings Details
8/11/2014($0.37)($0.38)ViewN/AView Earnings Details
5/12/2014Q114($0.35)($0.37)ViewN/AView Earnings Details
3/13/2014Q413($0.29)($0.31)ViewN/AView Earnings Details
8/7/2013Q213($0.40)($0.38)ViewN/AView Earnings Details
5/10/2013Q1 2013($0.35)($0.41)ViewN/AView Earnings Details
3/18/2013Q412($0.28)($0.47)$0.00 million$0.00 millionViewN/AView Earnings Details
11/13/2012Q312($0.24)($0.30)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Repros Therapeutics (NASDAQ:RPRX)
Current Year EPS Consensus Estimate: $-0.7 EPS

Dividends

Dividend History for Repros Therapeutics (NASDAQ:RPRX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Repros Therapeutics (NASDAQ:RPRX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/18/2016Joseph PodolskiCEOBuy10,000$0.93$9,300.00View SEC Filing  
1/7/2016Joseph PodolskiCEOBuy11,677$1.18$13,778.86View SEC Filing  
11/12/2014Joseph PodolskiCEOBuy4,700$9.42$44,274.00View SEC Filing  
11/12/2014Katherine AndersonCFOBuy3,500$9.41$32,935.00View SEC Filing  
8/14/2014Joseph PodolskiCEOBuy2,100$13.91$29,211.00View SEC Filing  
8/14/2014Katherine AndersonCFOBuy2,000$13.85$27,700.00View SEC Filing  
10/25/2013Joseph PodolskiCEOBuy3,000$18.03$54,090.00View SEC Filing  
10/25/2013Katherine AndersonCFOBuy1,000$17.90$17,900.00View SEC Filing  
10/10/2013Katherine AndersonCFOBuy1,000$23.77$23,770.00View SEC Filing  
2/1/2013Katherine AndersonCFOBuy1,000$11.89$11,890.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Repros Therapeutics (NASDAQ:RPRX)
DateHeadline
investornewswire.com logoWill Repros Therapeutics Inc. (NASDAQ:RPRX) Hit $2 Price Target? - Investor Newswire (NASDAQ:RPRX)
www.investornewswire.com - August 22 at 11:47 AM
biz.yahoo.com logoREPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure (NASDAQ:RPRX)
biz.yahoo.com - August 18 at 7:28 PM
finance.yahoo.com logoREPROS THERAPEUTICS INC. Financials (NASDAQ:RPRX)
finance.yahoo.com - August 17 at 7:33 PM
streetinsider.com logoRepros Therapeutics (RPRX) Issues Update on Enclomiphene Study vs. Diet and Exercise in Secondary Hypogonadal Men (NASDAQ:RPRX)
www.streetinsider.com - August 16 at 10:31 AM
zacks.com logoRepros Presents 6-Month Interim Data on Enclomiphene (NASDAQ:RPRX)
www.zacks.com - August 16 at 10:31 AM
4-traders.com logoRepros Therapeutics : Provides Six Month Interim Results for Enclomiphene Study in Obese Secondary Hypogonadal Men (NASDAQ:RPRX)
www.4-traders.com - August 16 at 10:31 AM
biz.yahoo.com logoREPROS THERAPEUTICS INC. Files SEC form 8-K, Other Events (NASDAQ:RPRX)
biz.yahoo.com - August 15 at 7:35 PM
finance.yahoo.com logo4:03 pm Repros Therapeutics provides a six month update on results from its ongoing 15 month study of secondary hypogonadal men of diet and exercise in combination with enclomiphene treatment (NASDAQ:RPRX)
finance.yahoo.com - August 15 at 7:35 PM
publicnow.com logoRepros Provides Six Month Interim Results for Enclomiphene Study in Obese Secondary Hypogonadal Men (NASDAQ:RPRX)
www.publicnow.com - August 15 at 7:35 PM
globenewswire.com logoRepros Therapeutics Inc.® Reports Second Quarter 2016 Financial Results - GlobeNewswire (press release) (NASDAQ:RPRX)
globenewswire.com - August 11 at 10:29 AM
cnbc.com logoRepros Therapeutics reports 2Q loss (NASDAQ:RPRX)
www.cnbc.com - August 10 at 10:19 AM
biz.yahoo.com logoREPROS THERAPEUTICS INC. Files SEC form 8-K, Results of Operations and Financial Condition (NASDAQ:RPRX)
biz.yahoo.com - August 9 at 10:27 AM
publicnow.com logoRepros Therapeutics Inc.® Reports Second Quarter 2016 Financial Results (NASDAQ:RPRX)
www.publicnow.com - August 9 at 10:27 AM
finance.yahoo.com logoRepros (RPRX) Q2 Earnings: What's in Store for the Stock? (NASDAQ:RPRX)
finance.yahoo.com - August 4 at 10:22 AM
equities.com logoRepros Therapeutics Inc. (RPRX) Jumps 17.78% on July 29 - Equities.com (NASDAQ:RPRX)
www.equities.com - July 30 at 9:59 AM
equities.com logoRepros Therapeutics Inc. (RPRX) Jumps 5.88% on July 28 - Equities.com (NASDAQ:RPRX)
www.equities.com - July 29 at 10:13 AM
equities.com logoRepros Therapeutics Inc. (RPRX) Drops 5.08% on July 25 - Equities.com (NASDAQ:RPRX)
www.equities.com - July 27 at 10:15 AM
News IconChecking in on Stock Volatility for: Repros Therapeutics Inc. (NASDAQ:RPRX) - Engelwood Daily (NASDAQ:RPRX)
www.engelwooddaily.com - July 21 at 7:31 PM
News IconPerformance watch list: Repros Therapeutics Inc. (NASDAQ:RPRX) - News Oracle (NASDAQ:RPRX)
www.newsoracle.com - July 21 at 7:31 PM
News IconStock Bending Down in Today's Session: Repros Therapeutics Inc. (NASDAQ:RPRX) - TGP (NASDAQ:RPRX)
telanaganapress.com - July 20 at 8:04 PM
News IconNews review of 2 biotech stocks: Repros Therapeutics (RPRX), Eleven Biotherapeutics (EBIO) - The Voice Registrar (NASDAQ:RPRX)
voiceregistrar.com - July 20 at 8:04 PM
equities.com logoRepros Therapeutics Inc. (RPRX) Jumps 16.57% on July 19 - Equities.com (NASDAQ:RPRX)
www.equities.com - July 20 at 8:04 PM
investornewswire.com logoStrong Sell Calls For Repros Therapeutics Inc. (NASDAQ:RPRX) At 0 - Investor Newswire (NASDAQ:RPRX)
www.investornewswire.com - July 18 at 12:43 PM
News IconShares Moving Down on the Week: Repros Therapeutics Inc. (NASDAQ:RPRX) - Engelwood Daily (NASDAQ:RPRX)
www.engelwooddaily.com - July 17 at 11:17 AM
kcregister.com logoBiogen Inc. (NASDAQ:BIIB) Increased 0.67%: Repros Therapeutics Inc. (NASDAQ:RPRX), Bristol-Myers Squibb ... - KC Register (NASDAQ:RPRX)
www.kcregister.com - July 16 at 10:26 AM
News IconAnalyst Target and Average Rating Watch: Repros Therapeutics Inc. (NASDAQ:RPRX) - Press Telegraph (NASDAQ:RPRX)
presstelegraph.com - July 16 at 10:26 AM
News IconRepros Therapeutics Incorporated (NASDAQ:RPRX) Shorts Decreased by 16.84% After Short Covering - Consumer Eagle (NASDAQ:RPRX)
www.consumereagle.com - July 13 at 10:05 AM
News IconRepros Therapeutics Inc. (NASDAQ:RPRX) Wall Street Analyst Recommendation Outlook - Telanagana Press (NASDAQ:RPRX)
telanaganapress.com - July 13 at 10:05 AM
fiscalstandard.com logoBrokers Issue Average Price Target Of 10.67 On Repros Therapeutics Inc. (RPRX) - Fiscal Standard (NASDAQ:RPRX)
www.fiscalstandard.com - July 9 at 10:16 AM
News IconHeightened Volatility Check on: Repros Therapeutics Inc. (NASDAQ:RPRX) - Engelwood Daily (NASDAQ:RPRX)
www.engelwooddaily.com - July 8 at 7:09 PM
News IconCan Repros Therapeutics Inc. (NASDAQ:RPRX) Improve on the Earnings Front? - Engelwood Daily (NASDAQ:RPRX)
www.engelwooddaily.com - July 8 at 7:09 PM
News IconCompany Stock Focus for Repros Therapeutics Inc. (NASDAQ:RPRX): Which Way Will Shares Head? - Press Telegraph (NASDAQ:RPRX)
presstelegraph.com - July 8 at 7:09 PM
News Icon2016 Q1 Sentiment Repros Therapeutics Inc (NASDAQ:RPRX) - Engelwood Daily (NASDAQ:RPRX)
www.engelwooddaily.com - July 8 at 7:09 PM
News IconRepros Therapeutics Inc. (NASDAQ:RPRX) Stock Update: Check on Ratings and Target Price - Telanagana Press (NASDAQ:RPRX)
telanaganapress.com - July 6 at 11:51 AM
investornewswire.com logoRepros Therapeutics Inc. (NASDAQ:RPRX) Expected to Reach Highs Of $2 - Investor Newswire (NASDAQ:RPRX)
www.investornewswire.com - July 5 at 11:37 AM
fiscalstandard.com logoBroker Outlook For The Week Ahead Repros Therapeutics Inc. (RPRX) - Fiscal Standard (NASDAQ:RPRX)
www.fiscalstandard.com - July 5 at 11:37 AM
News IconRepros Therapeutics Incorporated (NASDAQ:RPRX) Sellers Covered 16.84% of Their Shorts - Press Telegraph (NASDAQ:RPRX)
presstelegraph.com - July 2 at 9:53 AM
News IconAre Analysts Bullish Repros Therapeutics Inc (NASDAQ:RPRX) After Last Week? - Engelwood Daily (NASDAQ:RPRX)
www.engelwooddaily.com - June 30 at 7:27 PM
ftsenews.co.uk logoNew Broker Ratings For Repros Therapeutics Inc. (RPRX) - FTSE News (NASDAQ:RPRX)
www.ftsenews.co.uk - June 30 at 10:01 AM
News IconRepros Therapeutics Inc. (NASDAQ:RPRX) Company Rating and Target Watch - Telanagana Press (NASDAQ:RPRX)
telanaganapress.com - June 30 at 10:01 AM
equities.com logoRepros Therapeutics Inc. (RPRX) Jumps 5.44% on June 28 - Equities.com (NASDAQ:RPRX)
www.equities.com - June 30 at 10:01 AM
News IconCheck on Share Volatility: Repros Therapeutics Inc. (NASDAQ:RPRX) - Engelwood Daily (NASDAQ:RPRX)
www.engelwooddaily.com - June 28 at 7:06 PM
News IconRepros Therapeutics Incorporated (NASDAQ:RPRX) Short Interest Decreased By 16.84% - Engelwood Daily (NASDAQ:RPRX)
www.engelwooddaily.com - June 28 at 7:06 PM
News IconShare Update and Earnings Review for Repros Therapeutics Inc. (NASDAQ:RPRX) - Press Telegraph (NASDAQ:RPRX)
presstelegraph.com - June 27 at 11:20 AM
fiscalstandard.com logoNext Weeks Broker Price Targets For Repros Therapeutics Inc. (RPRX) - Fiscal Standard (NASDAQ:RPRX)
www.fiscalstandard.com - June 27 at 11:20 AM
investornewswire.com logoStrong Sell Calls Recommendations For Repros Therapeutics Inc. (NASDAQ:RPRX) At 0 - Investor Newswire (NASDAQ:RPRX)
www.investornewswire.com - June 26 at 6:12 PM
News IconShare Volatility Check for: Repros Therapeutics Inc. (NASDAQ:RPRX) - Press Telegraph (NASDAQ:RPRX)
presstelegraph.com - June 26 at 11:37 AM
News IconWere Analysts Bullish Repros Therapeutics Inc (NASDAQ:RPRX) This Week? - Press Telegraph (NASDAQ:RPRX)
presstelegraph.com - June 24 at 9:46 AM
News IconCovering the Bases on Repros Therapeutics Inc. (NASDAQ:RPRX): Where is the Stock Going? - Press Telegraph (NASDAQ:RPRX)
presstelegraph.com - June 24 at 9:46 AM
News IconRepros Therapeutics Inc. (NASDAQ:RPRX) Earnings Glance and Target Price Review - Engelwood Daily (NASDAQ:RPRX)
www.engelwooddaily.com - June 24 at 9:46 AM

Social

Repros Therapeutics (NASDAQ:RPRX) Chart for Sunday, August, 28, 2016


Last Updated on 8/28/2016 by MarketBeat.com Staff